Universitat Autònoma de Barcelona-ko ikertzaileekin lankidetzan egindako argitalpenak (5)

2025

  1. Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignancies

    The Lancet Haematology, Vol. 12, Núm. 6, pp. e470-e481

2020

  1. EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies

    ESMO Open, Vol. 5, Núm. 1

2019

  1. Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma

    Biology of Blood and Marrow Transplantation, Vol. 25, Núm. 9, pp. 1703-1712

2015

  1. Critical analysis of the stringent complete response in multiple myeloma: Contribution of sFLC and bone marrow clonality

    Blood, Vol. 126, Núm. 7, pp. 858-862

2005

  1. Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning

    Biology of Blood and Marrow Transplantation, Vol. 11, Núm. 6, pp. 437-447